Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on April 2, 2021, covering events occurring on March 30 and March 31, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Menlo Park, California. The filing primarily addresses corporate governance changes, executive compensation adjustments, and unregistered equity issuances.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics, as this report focuses on specific corporate events rather than periodic financial performance.
Material Changes and Corporate Actions
- Consulting Agreement Amendment: On March 31, 2021, the Company amended its consulting agreement with Prof. Jagdeep Nanchahal. The amendment added CannBioRex Pharma Limited, an indirect wholly-owned subsidiary, as a party to the agreement. This change facilitates cash payments to Prof. Nanchahal being made by the subsidiary for tax purposes and updates the timing of certain cash bonuses.
- Unregistered Equity Issuances: On March 30, 2021, the Board approved the issuance of restricted common stock to four key executives under the 2020 Omnibus Incentive Plan. These shares represented 50% of the amounts owed for services rendered:
- Prof. Marc Feldmann (Co-Executive Chairman): 20,910 shares
- Dr. Lawrence Steinman (Co-Executive Chairman): 22,585 shares
- Dr. Jonathan Rothbard (Chief Scientific Officer): 24,307 shares
- Prof. Jagdeep Nanchahal (Chairman, Clinical Advisory Committee): 100,699 shares
- Valuation Methodology: Shares issued to Prof. Feldmann, Dr. Rothbard, and Dr. Steinman were valued at the closing sales price on March 29, 2021. Shares issued to Prof. Nanchahal were valued at $3.00 per share.
- Leadership Appointment: Effective March 30, 2021, Ozan Pamir, the Interim Chief Financial Officer, was appointed as Secretary of the Company.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond standard securities law disclosures. The equity issuances were made pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D exemptions, noting that the securities are subject to transfer restrictions and may not be sold absent registration or an exemption.
Investor Verification Checklist
- Verify the exact closing stock price on March 29, 2021, to confirm the valuation of shares issued to Prof. Feldmann, Dr. Steinman, and Dr. Rothbard.
- Review the full text of the First Amendment to the Consultancy Agreement (Exhibit 10.2) to understand the specific tax implications and bonus timing changes for Prof. Nanchahal.
- Confirm the total number of shares outstanding post-issuance to assess the dilution impact of the 168,501 newly issued restricted shares.
- Check subsequent filings to determine if Ozan Pamir's role as Interim CFO has been made permanent or if a permanent CFO has been appointed.